Hemerion participated for the first time this year in the Annual Meeting of the Congress of Neurosurgeons, the world’s largest event dedicated to neurosurgery, held in Los Angeles.
Its combined Pentalafen®/Heliance® therapy attracted the attention of practitioners from around the world, as well as leading names in medtech.
The Hemerion team presented its Heliance®/Pentalafen® combination therapy for the treatment of glioblastoma at the Annual Meeting of the Congress of Neurosurgeons and during the Joint Tumor Section (an event specifically dedicated to brain tumors) in Los Angeles from October 9 to 15, 2025.
Hemerion is one of four French companies participating in this leading event dedicated to neurosurgery.
Committed practitioners, ready to take part in clinical development
For almost a week, international neurosurgeons had the opportunity to operate the illumination platform and assess its integration into a standard surgical procedure for tumor resection.
These discussions generated significant interest in participating in the pivotal phase clinical trial for the treatment of glioblastoma, which could be launched as early as 2026.
A presentation of the latest clinical data
The CNS annual meeting also offered a prime opportunity to present Hemerion’s clinical results in glioblastoma treatment to the neurosurgical community.
- Professor Costas Hadjipanayis, member of Hemerion’s Scientific Board, executive vice-chair for the University of Pittsburgh Neurological Surgery, director of the UPMC Center for Image-Guided Neurosurgery (CIGNS) and co-director of the UPMC Brain Tumor Center, presented a poster showing the initial results of the clinical trial currently being conducted at UPMC and Lille University Hospital entitled “The First US Phase I Trial for 5-ALA Photodynamic Therapy of Glioblastoma: An Innovative Drug-Device Combination”.
- Prof. Nicolas Reyns, member of Hemerion’s Scientific Board and co-inventor of the Pentalafen® / Heliance® technology, spoke at the Joint Tumor Section to present his work on the use of intraoperative photodynamic therapy in the treatment of glioblastoma.
Advanced contacts with leading players in the medtech sector
Hemerion’s technology has also attracted considerable interest from major players in the medtech sector. Several avenues for integrating this technology into the solutions offered by these leaders have been explored.
